Investigation of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Matrix Metalloproteinase Inhibitor-1, and Tissue Matrix Metalloproteinase Inhibitor-2 levels in preeclamptic and eclamptic pregnancy

The present research was designed to investigate levels of matrix metalloproteinase -2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and their respective tissue inhibitors, tissue matrix metalloproteinase inhibitor -1 (TIMP-1) and tissue matrix metalloproteinase inhibitor-2 (TIMP-2), in eclamptic and preeclamptic pregnant women.In this work, undertaken in the Obstetrics and Gynecology Department of the Yznc Yl University Faculty of Medicine Health Practice and Research Hospital, eclamptic (n=28), preeclamptic (n=28), and healthy pregnant women (n=24) were enrolled and their levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were studied by micro-ELISA method.No statistically meaningful differences were identified between the study groups for MMP -2 (p=0.786).When the ratios of MMP-2 to TIMP-2 of the three groups were examined, again, no statistically meaningful differences were noted (p=0.788).While a meaningful difference was not seen between the preeclamptic and eclamptic groups for MMP -9 and TIMP-1, significantly lower values of MMP-9 and TIMP-1 were obtained in both groups upon comparison to the control group (p=0.001 for MMP-9, p<0.000 for TIMP-1).When the MMP-9/TIMP-1 ratios of the groups were evaluated, a statistically meaningful difference did not exist between women with preeclampsia and controls; however, this ratio was higher among women with eclampsia in comparison to the preeclampsia and control groups and this finding was statistically significantly (p=0.011).Imbalanced levels of MMP-9 and TIMP-1 could be used as a marker in efforts to predict preeclampsia and especially eclampsia.However, larger clinical studies are needed to reveal these interactions in more detail.